Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
- Resource Type
- letter
- Authors
- Lee, Matthew M.Y.; Gillis, Keith A.; Brooksbank, Katriona J.M.; Allwood-Spiers, Sarah; Hall Barrientos, Pauline; Wetherall, Kirsty; Roditi, Giles; AlHummiany, Bashair; Berry, Colin; Campbell, Ross T.; Chong, Victor; Coyle, Liz; Docherty, Kieran F.; Dreisbach, John G.; Kuehn, Bernd; Labinjoh, Catherine; Lang, Ninian N.; Lennie, Vera; Mangion, Kenneth; McConnachie, Alex
- Source
- Circulation. 7/26/2022, Vol. 146 Issue 4, p364-367. 4p.
- Subject
- *EMPAGLIFLOZIN
*TYPE 2 diabetes
*VENTRICULAR ejection fraction
*HEART failure
*KIDNEYS
*SODIUM-glucose cotransporter 2 inhibitors
- Language
- ISSN
- 0009-7322
We studied effects of these drugs using kidney magnetic resonance imaging (MRI). Reproducibility kidney MRI analyses are published elsewhere.[3] Where both kidneys could not be aligned within the same coronal oblique view, the right kidney was prioritized. Keywords: clinical trial; diabetes mellitus; empagliflozin; heart failure; kidney; magnetic resonance imaging; sodium-glucose transporter 2 inhibitors EN clinical trial diabetes mellitus empagliflozin heart failure kidney magnetic resonance imaging sodium-glucose transporter 2 inhibitors 364 367 4 07/25/22 20220726 NES 220726 Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of worsening kidney function in patients with heart failure and reduced ejection fraction (HFrEF).[1] Comparatively little is known about the effects of these drugs on kidney perfusion in the setting of randomized controlled trials. [Extracted from the article]